Table 3.
Main exposure | Crude (unweighted) estimates |
Adjusted for confounding and censoring |
|||
---|---|---|---|---|---|
HR | 95% CI | HR | 95% CI | ||
Model 1 | AllPTB | 1.71 | 1.31-2.23 | 1.06 | 0.75-1.49 |
Model 2 | > 120 days | 1.89 | 1.17-3.06 | 1.25 | 0.65-2.43 |
61-120 days | 1.34 | 0.80-2.23 | 0.89 | 0.48-1.63 | |
31-60 days | 1.62 | 0.97-2.72 | 1.08 | 0.59-1.98 | |
≤ 30 days | 2.02 | 1.31-3.11 | 1.28 | 0.78-2.10 |
Model 1estimates the effect of prevalent, treated PTB on outcome of mortality. Model 2 estimates the effect of the same exposure by length delay between initiation of PTB treatment and initiation of HAART. Both models adjust for both confounding by baseline factors and LTFU using inverse probability of exposure and censoring weights; components and specification of weight models are described in the Appendix.